Johnson & Johnson ($JNJ) was aware of the alarming failure rates of ASR hip implants a year before the company stopped making them and two years before they were recalled, newly unsealed court documents show. Report | Report (sub. req.)
| Wednesday, June 3rd | 11am ET / 8am PT | Presented by: Capsugel
This webinar will explore capsules' utility in a range of applications, including bioavailability enhancement, modified release, pediatric solutions, & fixed dose combinations. Learn more about how capsules enable rapid advancement of products built on QbD principles and supported by PAT. Register today!
FiercePharma is the pharma industry's daily monitor, with a special focus on pharmaceutical company news and the market development of FDA approved products. Join 150,000+ pharma industry leaders who get FiercePharma via daily email. Click here to get your free weekly email briefing today!